Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Immune Checkpoint Inhibitors: Review of the Existing Evidence and Challenges in Breast Cancer Publisher Pubmed



Jalalvand M1, 2 ; Darbeheshti F3, 4 ; Rezaei N5, 6, 7
Authors

Source: Immunotherapy Published:2021


Abstract

Cancer initiation and progression are associated with immune system responses. Tumor cells use various tricks to scape of immune system, such as activating immune checkpoint pathways that induce immunosuppressive functions. Among the different immune checkpoint receptors, CTLA-4 and PD-1/PD-L1 are prominent therapeutic targets in different cancers. Although the US FDA has approved some immune checkpoint inhibitors for several cancers, concerning breast cancer still different clinical trials are looking for optimizing efficacy and decreasing immune-related adverse events. This review will discuss the existing body of knowledge with regard to cross-talk between immune system and tumor cells and then explore immune checkpoint-related signaling pathways in the context of breast tumors. Finally, we highlight the application of different immune checkpoint blockers in breast cancer patients. © 2021 Immunotherapy. All rights reserved.
Related Docs
View other Related Docs
1. Tumor Immunology, Clinical Immunology (2022)
2. Tumor Immunotherapies by Immune Checkpoint Inhibitors (Icis); the Pros and Cons, Cell Communication and Signaling (2022)
3. Immune Checkpoint Inhibitor (Ici) Therapy in Central Nervous System Cancers: State-Of-The-Art and Future Outlook, International Immunopharmacology (2025)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (8)
Fereydon Memari (1)
Other Related Docs
4. Ctla-4: As an Immunosuppressive Immune Checkpoint in Breast Cancer, Current Molecular Medicine (2023)
5. Immune Checkpoint Inhibitors for Triple-Negative Breast Cancer: From Immunological Mechanisms to Clinical Evidence, International Immunopharmacology (2021)
6. Immunopathology and Immunotherapy for Breast Cancer, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
7. Immunotherapy of Cancers Comes of Age, Expert Review of Clinical Immunology (2017)
8. Resistance to Immunotherapy in Human Malignancies: Mechanisms, Research Progresses, Challenges, and Opportunities, Journal of Cellular Physiology (2022)
9. Nano-Immunotherapy: Overcoming Delivery Challenge of Immune Checkpoint Therapy, Journal of Nanobiotechnology (2023)
10. Immune Checkpoint Inhibitors in Cancer Therapy, Current Oncology (2022)
11. Immunotherapy a New Hope for Cancer Treatment: A Review, Pakistan Journal of Biological Sciences (2018)
12. Understanding the Tumor Microenvironment for Effective Immunotherapy, Medicinal Research Reviews (2021)
13. The Tale of Tils in Breast Cancer: A Report From the International Immuno-Oncology Biomarker Working Group, npj Breast Cancer (2021)
14. Pd-1 and Cancer: Molecular Mechanisms and Polymorphisms, Immunogenetics (2018)
15. Resistance Mechanisms to Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Inhibitors, Expert Opinion on Biological Therapy (2021)
16. Pd-1/Pd-L1 Blockade: Prospectives for Immunotherapy in Cancer and Autoimmunity, IUBMB Life (2021)
17. Immune Microenvironment in Different Molecular Subtypes of Ductal Breast Carcinoma, Breast Cancer Research and Treatment (2021)
18. Pd-1/Pd-L1 Pathway: Basic Biology and Role in Cancer Immunotherapy, Journal of Cellular Physiology (2019)
19. Pdl1 Positivity Rate Between Triple-Negative and Non-Luminal Her2+ Cases, Current Cancer Therapy Reviews (2022)
20. A Comprehensive Review About the Utilization of Immune Checkpoint Inhibitors and Combination Therapy in Hepatocellular Carcinoma: An Updated Review, Cancer Cell International (2022)